Consensus $190.2M. Sees FY25 operating expenses in the range of $150.0M to $160.0M, a decrease from the previous guidance range of $165.0 million to $170.0 million and now representing an implied increase of 10% to 18% compared to 2024.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight Gains Competitive Edge with Market Shifts and Expansion Opportunities
- BofA sees Bausch + Lomb IOL recall news as positive for RxSight
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- RxSight price target lowered to $36 from $60 at BofA
- RxSight’s Path to Profitability: A Buy Rating Amid Revenue Growth and Operational Leverage